Business
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
HOUSTON, December 23, 2025--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces that Health Canada has accepted, without objection, the Clinical Trial Application (CTA) for COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS). The CTA acceptance by Health Canada allows for activation of clinical si
About this update from Coya Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/8e9a14c1a14eecbc36f6a6652e0410e6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BDDZG2KqdXzfSu7I7GDDlg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/8e9a14c1a14eecbc36f6a6652e0410e6","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/7LY82KD_BgR504Poi5QNEg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/8e9a14c1a14eecbc36f6a6652e0410e6","width":1024,"height":512}},"lazy":false},{"type":"text","content":"The CTA No Objection Letter from Health Canada allows for initiation of patient enrollment in the ALSTARS Trial at Canadian ALS centers.","length":136,"tagName":"p","attribs":{}},{"type":"text","content":"The ALSTARS Trial is a phase 2, placebo-controlled study that includes clinical sites in the United States and Canada to evaluate the efficacy and safety of COYA 302 for the treatment of ALS","length":190,"tagName":"p","attribs":{}},{"type":"text","content":"The ALSTARS Trial is underway in the United States and will now proceed in Canada","length":81,"tagName":"p","attribs":{}},{"type":"text","content":"HOUSTON, December 23, 2025--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces that Health Canada has accepted, without objection, the Clinical Trial Application (CTA) for COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS). The CTA acceptance by Health Canada allows for activation of clinical sites in Canada, enhancing patient recruitment alongside the U.S. clinical sites.","length":616,"tagName":"p"},{"type":"text","content":"Dr. Fred Grossman, Coya’s Chief Medical Officer, commented: "The activation of Canadian sites is an important step forward for the ALSTARS Trial that we believe will further enhance recruitment of this important study currently underway in the United States. We look forward to working with the Canadian ALS centers, with the goal of po...